Valeant Pharmaceuticals International has completed the previously announced acquisition of Salix Pharmaceuticals.
Valeant Pharmaceuticals International has completed the previously announced acquisition of Salix Pharmaceuticals.
The Laval, Que.-based company paid about US$11.1 billion or $173 a share for Salix.
Salix is a specialty pharmaceutical company that offers gastroenterology treatments.
As a result of the deal, Salix will become a wholly owned subsidiary of Valeant.
Also read:
Satwik Misra, CFA, MBA will be stepping into the newly created role of Director, Consultant Relationships & Business Initiatives, reflecting the continued growth and expansion...
On Oct. 18 in Toronto, the 2024 Healthy Outcomes Conference brought together nearly 140 benefits plan sponsors, experts and other industry thought leaders to exchange...
Plan sponsors are facing the perfect storm of rising benefits costs, a surge in chronic disease prevalence and fierce competition for top talent. All the...
While migraine is a complex neurological condition that can significantly impact patients’ quality of life and ability to work, it’s also poorly understood and often...
While nine in 10 (85 per cent) employers that reported decreased employee productivity over the past year cited burnout as a major problem, investing in...
Joey Restaurant Group is using an internal educational program to teach employees the soft skills of leadership and assist in their career development. By focusing on...
The average funded position of defined benefit pension plans in Ontario was 121 per cent in the third quarter of 2024, down just two per...
As plan sponsors contend with high utilization of their drug plans and a host of costly new drugs coming to market, a variety of cost-containment...